Immune checkpoint inhibitor targets T-cell regulatory pathways by blocking negative signal to enhance antitumor immune response, and led to anti-tumor effect. This therapy has shown a durable clinical response which can lead part of cancer patients a long survival time. With lessons learned from advanced melanoma, I propose some questions and try to discuss some of them.